Infiltrating mast cells enhance benign prostatic hyperplasia through IL-6/STAT3/Cyclin D1 signals

Zhenyu Ou; Yao He; Lin Qi; Xiongbin Zu; Longxiang Wu; Zhenzhen Cao; Yuan Li; Longfei Liu; Daud Athanasius Dube; Zhi Wang; Long Wang

doi:10.18632/oncotarget.19465

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Infiltrating mast cells enhance benign prostatic hyperplasia through IL-6/STAT3/Cyclin D1 signals

Zhenyu Ou, Yao He, Lin Qi, Xiongbin Zu, Longxiang Wu, Zhenzhen Cao, Yuan Li, Longfei Liu, Daud Athanasius Dube, Zhi Wang and Long Wang _

PDF | HTML | How to cite

Oncotarget. 2017; 8:59156-59164. https://doi.org/10.18632/oncotarget.19465

Metrics: PDF 1627 views | HTML 2962 views | ?

Abstract

Zhenyu Ou1, Yao He1, Lin Qi1, Xiongbin Zu1, Longxiang Wu1, Zhenzhen Cao2, Yuan Li1, Longfei Liu1, Daud Athanasius Dube3, Zhi Wang1 and Long Wang1

1Department of Urology, Xiangya Hospital, Central South University, Changsha, China

2Department of Gynecologic Oncology, The Affiliated Tumor Hospital of Xiangya Medical School, Central South University, Changsha, China

3Department of Urology, College of Health Sciences, University of Zimbabwe, Harare, Zimbabwe

Correspondence to:

Long Wang, email: [email protected]

Keywords: benign prostatic hyperplasia, mast cell, proliferation, chemokine

Received: October 19, 2016 Accepted: June 06, 2017 Published: July 22, 2017

ABSTRACT

Early evidences have showed that mast cells could infiltrate into benign prostatic hyperplasia (BPH) tissues, but the exact role of mast cells in BPH development remains unclear. In this study, we identified more mast cells existing in human BPH tissues compared with that in the normal prostate. In the in vitro co-culture system, BPH-1 prostate cells promoted activation and migration of mast cells, and mast cells conversely stimulated BPH-1 cells proliferation significantly. Molecular analysis demonstrated that mast cell-derived interleukin 6 (IL-6) could activate STAT3/Cyclin D1 signals in BPH-1 cells. Blocking IL-6 or STAT3 partially reverse the capacity of mast cells to enhance BPH-1 cell proliferation. Our findings suggest that infiltrating mast cells in BPH tissues could promote BPH development via IL-6/STAT3/Cyclin D1 signals. Therefore, targeting infiltrating mast cells may improve the therapeutic effect of BPH.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19465

Publication Alerts

Research Papers:

Infiltrating mast cells enhance benign prostatic hyperplasia through IL-6/STAT3/Cyclin D1 signals

Abstract